Abstract
Several clinical trials, post-marketing surveillance studies and a meta-analysis were performed to obtain information about dose finding, pharmacokinetics, special indications, tolerability and compliance. In eight clinical trials, according to GCP, 1463 patients were included. Six of the trials were double-blind studies against placebo, racemic ibuprofen and diclofenac; the pharmacokinetic study and a long-term safety study were open studies. A meta-analysis of five clinical trials compared tolerability and safety data between dexibuprofen and racemic ibuprofen. Three PMS studies collected data on 7133 outpatients. All clinical trials and PMS studies have been published. In the dosage ratio 0.5:1, dexibuprofen was found to be at least as efficacious as racemic ibuprofen; 75% of the maximum daily dose of dexibuprofen was equally efficacious as 100% of MDD of diclofenac; no influence was found of meals on bioavailability and a significant doseresponse relationship; there was clinical efficacy in rheumatoid arthritis, ankylosing spondylitis, osteoarthritis of the hip, osteoarthritis of the knee, lumbar vertebral syndrome, distortion of the ankle joint and dysmenorrhoea; there was good tolerability compared to other NSAIDs: racemic ibuprofen showed a 30% and diclofenac a 90 % higher incidence of adverse drug reactions; the longterm study stated a 15.2% adverse drug event incidence; the incidence of adverse drug reactions in the PMS studies was between 5.5% and 7.4%, and withdrawals were between 2.3% and 2.7%. In conclusion, dexibuprofen (Seractil®) has the stature of a modern NSAID, combining the high efficacy of diclofenac with the good tolerability of ibuprofen, and need not hide behind the new generation of COX-2 inhibitors.
Similar content being viewed by others
References
Adams S S, Bresloff P, Mason CG. Pharmacological differences between the optical isomeres of ibuprofen: evidence for metabolic inversion of (-)-isomer. J Pharm Pharmacol 1976;28:256–7.
Evans AM. Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen. J Clin Pharmacol 1996;36:7–15.
Klein G, Neff H, Kullich W, Phleps W, Kollenz CJ. S(+) versus racemic ibuprofen. Lancet 1992;339:681.
Rahlfs VW. Reevaluation of some double-blind randomized studies of dexibuprofen (Seractil): a state-of-the-art overview. J Clin Pharmacol 1996;36:S33–40.
Comparison of the bioavailability after a single-dose oral administration of tablets containing 400 mg S(+)ibuprofen under fasting and non-fasting conditions. Internal report Gebro Pharma 1/24.3, 1999.
Klein G., Hawel R., Wallner H., Kullich W. NSAR-Therapie: SchlieBt Wirksamkeit Vertraglichkeit aus? Klinische Erfahrungen mit dem neuen Antirheumatikum Dexibuprofen. Der praktische Arzt 1994;48:3–7.
Hawel R, Klein G, Mitterhuber J, Brugger A. A double-blind study to compare the efficacy and tolerance of dexibuprofen 900 mg with diclofenac sodium in patients with painful osteoarthritis of the knee. Wien Klin Wochenschr 1997;109:53–9.
Study to compare the efficacy and tolerability of dexibuprofen (200/300 mg) versus ibuprofen racemate 400 mg in patients suffering from primary dysmenorrhea. Internal report Gebro Pharma III/21.3, 1998.
Singer F et al. Evaluation of the efficacy and doseresponse relationship of dexibuprofen (S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index. Clinical pharmacology and therapeutics No. 1/2000; Volume 38:15–24.
Eichler HG, Sycha T. Evaluation of the long-term safety of Seractil® film-coated tablets. Jan. 2000; Data on file.
Internal Report Gebro Pharma. 2001.
Chlud, K. Evaluation of tolerance and efficacy of S(+)-ibuprofen (Seractil) in daily practice: a post-marketing-surveillance study in 1400 patients. J Clin Pharmacol 1995;35:938.
Ceraso OL. Estudio de farmacovigilancia (fase IV) con dextroibuprofeno, Análisis sobre 5.322 casos. Pren Méd Argent 1998;85:923–31.
Bartalski L. Seractil® forte 400 mg-Filmtabletten bei der Behandlung postoperativer und posttraumatischer Schmerz-zustände. Clinicum 1999;10:1–8.
Peterson W. L. COX-1-Sparing NSAIDs - is the enthusiasm justified? JAMA 1999;282:1921–8.
Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteriodal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284:1247–55.
Langman MJS, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929–33.
Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769–72.
Feldmann M. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000;132:134–43.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Phleps, W. Overview on Clinical Data of Dexibuprofen. Clin Rheumatol 20 (Suppl 1), 15–21 (2001). https://doi.org/10.1007/BF03342663
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03342663